SCHEMBL6774774

SCHEMBL6774774

CN1CCCC1CCNc1nc(C2(c3ccccc3F)CCCCC2)cs1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 2/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
RAD52 P43351 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ERAP1 Q9NZ08 1/20 0.37
CHRM3 P20309 3/20 0.37
ACP1 P24666 2/20 0.37
HSD11B1 P28845 1/20 0.34
HSD11B2 P80365 1/20 0.34
SLC2A1 P11166 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845392 0.81 BACE1 (0.46) ACKR3HRH2HRH1HRH3NOS3
SCHEMBL5845190 0.79 BACE1 (0.44) ACKR3HRH2HRH1HRH3NOS3
SCHEMBL5845604 0.74 BACE1 (0.39) ACKR3HRH2HRH1HRH3NOS3
SCHEMBL13698605 0.70 HSD11B1 (0.40) NPC1RAB9AHSD11B1HSD11B2
SCHEMBL13698399 0.69 HSD11B1 (0.39) HRH1HSD11B1HSD11B2
SCHEMBL5845448 0.69 HRH4 (0.38) HRH3NPC1RAB9AHSD11B1HSD11B2
SCHEMBL14113978 0.69 HSD11B1 (0.35) HSD11B1HSD11B2
SCHEMBL13988690 0.68 SIGMAR1 (0.34) HRH1HSD11B1HSD11B2
SCHEMBL1913776 0.67 NOS3 (0.58) ACKR3HRH2HRH1HRH3NOS3
SCHEMBL8279664 0.66 BACE1 (0.55) NPC1RAB9AHSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699866-B2 FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS SEPRACOR INC. 2004-03-02 US disclosed
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-06-05 US disclosed
WO-2002083863-A2 THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF SEPRACOR, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof HTR5A, OPRL1, HTR2C ACKR3 1181/4885HRH2 124/4885HRH1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.